Cc Daily Correct Broad Spectrum Spf 35 Sunscreen Supergoop

Cc Daily Correct Broad Spectrum Spf 35 Sunscreen Supergoop Manufacturers

• Taylor James, Ltd.
  

  ×

  Cc Daily Correct Broad Spectrum Spf 35 Sunscreen Supergoop | Taylor James, Ltd.

  

  ---

  Directions

  Apply liberally 15 minutes before sun exposure

  Use a water resistant sunscreen if swimming or sweating

  Reapply at least every 2 hours

  Children under 6 months: Ask a doctor

  Sun Protection Measures: Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regualarly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including:

  Limit time in the sun, especially from 10 a.m.-2p.m.

  Wear long sleeve shirts, pants, hats and sunglasses.

  Inactive Ingredients Water, Cylopentasiloxane, Propanediol, Dimethicone, Iron Oxides, Lauryl PEG-9, Polydimethylsiloxyethyl Dimethicone, Glycerin, Phenoxyethanol, Pyrus Malus (Apple) Fruit Extract, Sodium Chloride, Mica, Dimethicone/PEG-10/15 Crosspolymer, Titanium Dioxide, Triethoxycaprylylsilane, Silica, Dimethicone/Vinyl Dimethicone Crosspolymer, Chondrus Crispus Extract, Tetrasodium EDTA, Hydrolyzed Chondrus Crispus Extract, Methylisothiazolinone, Tin Oxide, Sodium Hyaluronate.

  Close
  No Recall

  More Info
• Taylor James, Ltd.
  

  ×

  Cc Daily Correct Broad Spectrum Spf 35 Sunscreen Supergoop | Cardinal Health

  

  ---

  Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who require doses greater than 4 mg/day. In such cases, dosage should be increased cautiously to avoid adverse effects.

  Anxiety Disorders and Transient Symptoms of Anxiety

  Treatment for patients with anxiety should be initiated with a dose of 0.25 to 0.5 mg given three times daily. The dose may be increased to achieve a maximum therapeutic effect, at intervals of 3 to 4 days, to a maximum daily dose of 4 mg, given in divided doses. The lowest possible effective dose should be employed and the need for continued treatment reassessed frequently. The risk of dependence may increase with dose and duration of treatment.

  In all patients, dosage should be reduced gradually when discontinuing therapy or when decreasing the daily dosage. Although there are no systematically collected data to support a specific discontinuation schedule, it is suggested that the daily dosage be decreased by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction.

  Panic Disorder

  The successful treatment of many panic disorder patients has required the use of ALPRAZOLAM at doses greater than 4 mg daily. In controlled trials conducted to establish the efficacy of ALPRAZOLAM in panic disorder, doses in the range of 1 to 10 mg daily were used. The mean dosage employed was approximately 5 to 6 mg daily. Among the approximately 1700 patients participating in the panic disorder development program, about 300 received ALPRAZOLAM in dosages of greater than 7 mg/day, including approximately 100 patients who received maximum dosages of greater than 9 mg/day. Occasional patients required as much as 10 mg a day to achieve a successful response.
  
  

  Dose Titration

  Treatment may be initiated with a dose of 0.5 mg three times daily. Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg per day. Slower titration to the dose levels greater than 4 mg/day may be advisable to allow full expression of the pharmacodynamic effect of ALPRAZOLAM. To lessen the possibility of interdose symptoms, the times of administration should be distributed as evenly as possible throughout the waking hours, that is, on a three or four times per day schedule.

  Generally, therapy should be initiated at a low dose to minimize the risk of adverse responses in patients especially sensitive to the drug. Dose should be advanced until an acceptable therapeutic response (ie, a substantial reduction in or total elimination of panic attacks) is achieved, intolerance occurs, or the maximum recommended dose is attained.
  
  

  Dose Maintenance

  For patients receiving doses greater than 4 mg/day, periodic reassessment and consideration of dosage reduction is advised. In a controlled postmarketing dose-response study, patients treated with doses of ALPRAZOLAM greater than 4 mg/day for 3 months were able to taper to 50% of their total maintenance dose without apparent loss of clinical benefit. Because of the danger of withdrawal, abrupt discontinuation of treatment should be avoided. (See WARNINGS, PRECAUTIONS, DRUG ABUSE AND DEPENDENCE.)

  The necessary duration of treatment for panic disorder patients responding to ALPRAZOLAM is unknown. After a period of extended freedom from attacks, a carefully supervised tapered discontinuation may be attempted, but there is evidence that this may often be difficult to accomplish without recurrence of symptoms and/or the manifestation of withdrawal phenomena.
  
  

  Dose Reduction

  Because of the danger of withdrawal, abrupt discontinuation of treatment should be avoided (see WARNINGS, PRECAUTIONS, DRUG ABUSE AND DEPENDENCE).

  In all patients, dosage should be reduced gradually when discontinuing therapy or when decreasing the daily dosage. Although there are no systematically collected data to support a specific discontinuation schedule, it is suggested that the daily dosage be decreased by no more than 0.5 mg every three days. Some patients may require an even slower dosage reduction.

  In any case, reduction of dose must be undertaken under close supervision and must be gradual. If significant withdrawal symptoms develop, the previous dosing schedule should be reinstituted and, only after stabilization, should a less rapid schedule of discontinuation be attempted. In a controlled postmarketing discontinuation study of panic disorder patients which compared this recommended taper schedule with a slower taper schedule, no difference was observed between the groups in the proportion of patients who tapered to zero dose; however, the slower schedule was associated with a reduction in symptoms associated with a withdrawal syndrome. It is suggested that the dose be reduced by no more than 0.5 mg every 3 days, with the understanding that some patients may benefit from an even more gradual discontinuation. Some patients may prove resistant to all discontinuation regimens.
  
  

  Dosing in Special Populations

  In elderly patients, in patients with advanced liver disease or in patients with debilitating disease, the usual starting dose is 0.25 mg, given two or three times daily. This may be gradually increased if needed and tolerated. The elderly may be especially sensitive to the effects of benzodiazepines. If side effects occur at the recommended starting dose, the dose may be lowered.

  Close
  No Recall

  More Info